Announcements
- Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.
- Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
- Spexis announces closing of sale of preclinical antibiotics program to Basilea
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 9.71 |
Average volume | -- |
---|---|
Shares outstanding | 67.66m |
Free float | 31.54m |
P/E (TTM) | -- |
Market cap | 3.98m CHF |
EPS (TTM) | -0.2547 CHF |
Data delayed at least 15 minutes, as of Jun 28 2019.
More ▼